136 related articles for article (PubMed ID: 2452773)
21. CA 125 in the follow-up of patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Eur J Obstet Gynecol Reprod Biol; 1988 Apr; 27(4):335-42. PubMed ID: 3164284
[TBL] [Abstract][Full Text] [Related]
22. [Simultaneous determination of Ca 125 and D-dimer in plasma and ascites in ovarian cancer].
Schröck R; Hafter R; Graeff H; Schmid L
Onkologie; 1985 Oct; 8(5):260-2. PubMed ID: 2999668
[TBL] [Abstract][Full Text] [Related]
23. Preoperative evaluation of CA 125 and CA 19-9 serum levels in patients with ovarian masses.
Fioretti P; Gadducci A; Ferdeghini M; Bartolini T; Fontana V; Facchini V
Eur J Gynaecol Oncol; 1988; 9(4):291-4. PubMed ID: 3164674
[TBL] [Abstract][Full Text] [Related]
24. CA 15-3 serum levels in ovarian cancer.
Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Di Roberto P; Mancuso S
Oncology; 1988; 45(3):263-7. PubMed ID: 3163419
[TBL] [Abstract][Full Text] [Related]
25. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
[TBL] [Abstract][Full Text] [Related]
26. CA 125 in gynecologic practice.
Malkasian GD; Podratz KC; Stanhope CR; Ritts RE; Zurawski VR
Am J Obstet Gynecol; 1986 Sep; 155(3):515-8. PubMed ID: 2428248
[TBL] [Abstract][Full Text] [Related]
27. Serum CA 125 levels in preoperative evaluation of pelvic masses.
Vasilev SA; Schlaerth JB; Campeau J; Morrow CP
Obstet Gynecol; 1988 May; 71(5):751-6. PubMed ID: 3162763
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
Koebl H; Tatra G; Bieglmayer C
Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
[TBL] [Abstract][Full Text] [Related]
29. [Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer. CA 125 as a tumor marker. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
Kaesemann H; Caffier H; Hoffmann FJ; Crombach G; Würz H; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G
Klin Wochenschr; 1986 Sep; 64(17):781-5. PubMed ID: 3463828
[TBL] [Abstract][Full Text] [Related]
30. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
Bast RC; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp RC
Cancer; 1991 Oct; 68(8):1758-63. PubMed ID: 1913520
[TBL] [Abstract][Full Text] [Related]
31. [Clinical usefulness of the combination assay of CA 125, SLX, and CA 72-4 in patients with ovarian cancer].
Kobayashi H; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1731-5. PubMed ID: 2574209
[TBL] [Abstract][Full Text] [Related]
32. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
Wu JT; Miya T; Knight JA; Knight DP
Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
[TBL] [Abstract][Full Text] [Related]
33. Serum copper in ovarian carcinoma.
Jacobs AJ; Sommers GM; Axelrod JH; Galakatos AE; Kao MS; Camel HM
Cancer; 1988 Mar; 61(5):1015-7. PubMed ID: 3422179
[TBL] [Abstract][Full Text] [Related]
34. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
35. CA 125 and TPA as markers in ovarian carcinoma.
Rodenburg CJ; De Maaker GA; Trimbos JB; Moolenaar AJ; Van Oosterom AT
Neth J Med; 1985; 28(12):536-40. PubMed ID: 2418375
[No Abstract] [Full Text] [Related]
36. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
37. Serum CA 125 in epithelial ovarian cancer. A longitudinal study.
Brioschi PA; Irion O; Bischof P; Bader M; Forni M; Krauer F
Br J Obstet Gynaecol; 1987 Mar; 94(3):196-201. PubMed ID: 3471273
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer.
Vergote IB; Børmer OP; Abeler VM
Am J Obstet Gynecol; 1987 Jul; 157(1):88-92. PubMed ID: 2440307
[TBL] [Abstract][Full Text] [Related]
39. Use of CA 125 monoclonal antibody to monitor patients with ovarian cancer.
Kudlacek S; Schieder K; Kölbl H; Neunteufel W; Nowotny C; Breitenecker G; Biegelmayer G; Vetterlein M; Fürlinger B; Micksche M
Gynecol Oncol; 1989 Dec; 35(3):323-9. PubMed ID: 2480931
[TBL] [Abstract][Full Text] [Related]
40. Comparative measurement of ovarian carcinoma antigen and carcinoembryonic antigen in the serum of ovarian cancer.
Yuan CC; Ng HT; Tsai LC; Jeng FS; Yeh SH; Tsai YC
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Aug; 20(3):190-7. PubMed ID: 3480793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
